186Rhenium-HNK1 monoclonal antibody targets human small cell lung cancer cells in athymic nude mice: rapid screening...

Area of Science:

• Oncology
• Immunology
• Radiopharmacology

Background:

• Investigating in vivo tumor-monoclonal antibody (MOAB) interactions is crucial for effective cancer therapy.
• Small cell lung cancer (SCLC) often metastasizes to the lungs, necessitating targeted treatment strategies.
• Current methods for evaluating MOAB efficacy in vivo can be time-consuming.

Purpose of the Study:

• To develop and validate a rapid in vivo model for assessing tumor-MOAB interactions.
• To evaluate the biodistribution of a specific MOAB (HNK1 MOAB, CD57) tagged with 186Rhenium in a small cell lung cancer model.
• To determine the model's utility in selecting appropriate MOABs for individualized patient treatment.

Main Methods:

• Establishment of a small cell lung cancer (SCLC) model in athymic nude mice by intravenous injection of SHP-77 cells.
• Intravenous administration of 186Rhenium-tagged HNK1 MOAB (CD57) 24 hours post-tumor cell inoculation.
• Biodistribution studies were conducted 24 hours after MOAB injection, comparing tumor-bearing mice with control groups.

Main Results:

• Significantly higher radioactivity was observed in the lungs of mice inoculated with both SHP-77 cells and 186Re MOAB compared to control groups.
• The model demonstrated rapid uptake and biodistribution of the targeted MOAB in the presence of tumor cells.
• Control groups (no tumor cells, unbound 186Re, or radioactive MOAB without tumor cells) showed different radioactivity patterns, validating the specificity of the observed results.

Conclusions:

• The described in vivo model is effective for investigating tumor-MOAB interactions.
• This rapid method can assist in selecting optimal MOABs for personalized treatment of small cell lung cancer.
• The biodistribution of 186Rhenium-tagged HNK1 MOAB (CD57) was successfully evaluated in a relevant preclinical model.